Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological Immunotherapie

NCT06031233 · clinicaltrials.gov ↗

PHASE4

Phase

RECRUITING

Status

776

Enrollment

OTHER

Sponsor class

Conditions

Oncology
Infusion Reaction

Interventions

DRUG: Nivolumab
DRUG: Pembrolizumab
DRUG: Ipilimumab
DRUG: Durvalumab
DRUG: Atezolizumab
DRUG: Bevacizumab
DRUG: Trastuzumab
DRUG: Rituximab

Sponsor

Isala